There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Leap Therapeutics (LPTX – Research Report) and Atara Biotherapeutics (ATRA – Research Report) with bullish sentiments.
Leap Therapeutics (LPTX)
In a report issued on January 23, Mara Goldstein from Mizuho Securities maintained a Buy rating on Leap Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $1.82.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of
Currently, the analyst consensus on Leap Therapeutics is a Strong Buy with an average price target of $5.67, representing a 220.3% upside. In a report issued on January 24, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.
Atara Biotherapeutics (ATRA)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics on January 24 and set a price target of $41.00. The company’s shares closed last Thursday at $9.55, close to its 52-week low of $8.24.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of
Atara Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $36.25, implying a 296.2% upside from current levels. In a report issued on March 1, Canaccord Genuity also maintained a Buy rating on the stock with a $67.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LPTX: